Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Duration of Anti-PD-1 Therapy in Metastatic Melanoma [Phase 3]
Phase 3 trial update examining the optimal duration of anti-PD-1 therapy for unresectable/metastatic melanoma.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating DOC1021 dendritic cell immunotherapy for refractory melanoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study [Phase 2]
A Phase 2 immunoMATCH pilot trial (BiCaZO) is evaluating cabozantinib in combination with nivolumab for advanced melanoma and head and neck …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer [Phase 1]
A Phase 1 trial update investigates pembrolizumab in combination with aflibercept in patients with advanced cancers, including melanoma, col…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
Clinical trial update for the SHERLOCK platform, a high-precision evaluation of minimal residual disease for cancer tracking and interceptio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma [Phase 2]
A Phase 2 clinical trial is evaluating GB1211 in combination with pembrolizumab versus pembrolizumab with placebo in patients with metastati…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating navitoclax in combination with dabrafenib and trametinib for patients with BRAF-mutant melanoma; th…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute's Cancer Moonshot Biobank update outlines the trial's status and scope, indicating the study is active but not rec…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: UK ENcorafenib and BInimetinib Real-world Study in Melanoma
A real-world UK study of encorafenib and binimetinib in metastatic melanoma with a BRAF V600 mutation; the study status is ACTIVE_NOT_RECRUI…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread [Phase 2]
Phase 2 clinical trial update evaluating two different schedules of dabrafenib and trametinib for stage III/IV or unresectable melanoma.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer [Phase 1]
Phase 1 trial update on MK-2206 plus hydroxychloroquine for advanced solid tumors, including melanoma, prostate cancer, and renal cell carci…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of TRK-950 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
This ClinicalTrials.gov entry reports an ongoing Phase 1/2 study of TRK-950 in patients with advanced solid tumors, including melanoma, that…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 study of TransCon TLR7/8 agonist with or without pembrolizumab in patients with advanced or metastatic solid tumors has been ter…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy [Phase 1, Phase 2]
Clinical trial evaluating oral 7HP349 (Alintegimod) in combination with ipilimumab, followed by nivolumab monotherapy, in patients with adva…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis [EARLY_Phase 1]
An EARLY Phase 1 trial evaluating RP1 in primary melanoma to reduce the risk of sentinel lymph node metastasis; the study is currently recru…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies [Phase 1]
Phase 1 trial update evaluating cediranib maleate and selumetinib sulfate in patients with solid malignancies, including metastatic melanoma…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Phase 1]
Phase 1 trial investigating riluzole in combination with sorafenib tosylate in patients with advanced solid tumors or melanoma; the study st…
-
EMA approval · 2026-04-09EMA Authorised: Tafinlar (dabrafenib mesilate) — Novartis Europharm Limited
The European Medicines Agency authorised Tafinlar, with the active substance dabrafenib mesilate, for melanoma; the marketing authorization …
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors [Phase 1]
Phase 1 update reporting safety, pharmacokinetics, and preliminary efficacy data for AI-061 in advanced solid tumors across multiple indicat…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations [Phase 2]
Phase 2 study evaluating patient preference for subcutaneous versus intravenous administration of nivolumab and the nivolumab-relatlimab fix…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) [Phase 2]
Phase 2 study compares subcutaneous pembrolizumab coformulated with hyaluronidase alfa (MK-3475A) to intravenous pembrolizumab in multiple t…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors [Phase 1, Phase 2]
GEN1042 is being evaluated in a Phase 1/2 safety study with indications across malignant solid tumors, including non-small cell lung cancer,…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) [Phase 1, Phase 2]
Clinical trial update on safety and efficacy of pembrolizumab alone or with investigational agents in first-line advanced melanoma (MK-3475-…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) [Phase 2]
A Phase 2 trial evaluating Acasunlimab alone and in combination with pembrolizumab for advanced melanoma that has relapsed after prior check…